|
1
|
Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, De la Cruz Vicente F, Machan S, Moya-Martínez C, Rovira R, Sanchez-Gonzalez B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, de Misa RF, Flórez A, Izu R, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero PL, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: data from the Spanish Primary Cutaneous Lymphoma Registry. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00634-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
|
2
|
Nagore E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, Martorell A, Bañuls J, Carrera C, Ortiz P, Gardeazabal J, Boada A, de Eusebio E, Chiner E, Gonzalez C, Pérez-Gil A, Cullen D, Formigón M, de Unamuno B, Navarro-Soriano C, Muriel A, Gozal D. Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: an observational multicentric study in 443 patients with melanoma. Br J Dermatol 2021; 185:756-763. [PMID: 33453061 DOI: 10.1111/bjd.19813] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 12/01/2020] [Accepted: 01/11/2021] [Indexed: 01/07/2023]
Abstract
BACKGROUND Some studies have suggested a relationship between type 2 diabetes mellitus (T2DM) and increased incidence of melanoma. Efforts are under way to identify preventable and treatable factors associated with greater melanoma aggressiveness, but no studies to date have examined the relationship between T2DM and the aggressiveness of cutaneous melanoma at diagnosis. OBJECTIVES To explore potential associations between T2DM, glycaemic control and metformin treatment and the aggressiveness of cutaneous melanoma. METHODS We conducted a cross-sectional multicentric study in 443 patients diagnosed with cutaneous melanoma. At diagnosis, all patients completed a standardized protocol, and a fasting blood sample was extracted to analyse their glucose levels, glycated haemoglobin concentration and markers of systemic inflammation. Melanoma characteristics and aggressiveness factors [Breslow thickness, ulceration, tumour mitotic rate (TMR), sentinel lymph node (SLN) involvement and tumour stage] were also recorded. RESULTS The mean (SD) age of the patients was 55·98 (15·3) years and 50·6% were male. The median Breslow thickness was 0·85 mm. In total, 48 (10·8%) patients were diagnosed with T2DM and this finding was associated with a Breslow thickness > 2 mm [odds ratio (OR) 2·6, 95% confidence interval (CI) 1·4-4·9; P = 0·004)] and > 4 mm (OR 3·6, 95% CI 1·7-7·9; P = 0·001), TMR > 5 per mm2 (OR 4·5, 95% CI 1·4-13·7; P = 0·009), SLN involvement (OR 2·3, 95% CI 1-5·7; P = 0·038) and tumour stages III-IV (vs. I-II) (OR 3·4, 95% CI 1·6-7·4; P = 0·002), after adjusting for age, sex, obesity, alcohol intake and smoking habits. No significant associations emerged between glycated haemoglobin levels, metformin treatment and melanoma aggressiveness. CONCLUSIONS T2DM, rather than glycaemic control and metformin treatment, is associated with increased cutaneous melanoma aggressiveness at diagnosis.
Collapse
Affiliation(s)
- E Nagore
- Dermatology Department, Instituto Valenciano de Oncologia, Valencia, Spain.,School of Medicine, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain
| | - M A Martinez-Garcia
- Pneumology Department, Hospital Universitario i Politécnico la Fe, Valencia, Spain.,CIBER de Enfermedades Respiratorias, ISCIII, Madrid, Spain
| | - J D Gomez-Olivas
- Pneumology Department, Hospital Universitario i Politécnico la Fe, Valencia, Spain
| | - E Manrique-Silva
- Dermatology Department, Instituto Valenciano de Oncologia, Valencia, Spain.,School of Medicine, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain
| | - A Martorell
- Dermatology Department, Hospital de Manises, Valencia, Spain
| | - J Bañuls
- Dermatology Department, Hospital General de Alicante, Alicante, Spain
| | - C Carrera
- Dermatology Department, Hospital Clinic, Barcelona, Spain
| | - P Ortiz
- Dermatology Department, Hospital 12 de Octubre, Madrid, Spain
| | - J Gardeazabal
- Dermatology Department, Hospital de Cruces, Bilbao, Spain
| | - A Boada
- Dermatology Department, Hospital Germans Trials i Pujol, Barcelona, Spain
| | - E de Eusebio
- Dermatology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain
| | - E Chiner
- Pneumology Department, Hospital San Juan de Alicante, Spain
| | - C Gonzalez
- Dermatology Department, Hospital d Getafe, Madrid, Spain
| | - A Pérez-Gil
- Dermatology Department, Hospital de Valme, Seville, Spain
| | - D Cullen
- Dermatology Department, Fundación Jiménez Diaz, Madrid, Spain
| | - M Formigón
- Dermatology Department, Consorcio Sanitario Terrassa, Barcelona, Spain
| | - B de Unamuno
- Dermatology Department, Hospital Universitario i Politécnico la Fe, Valencia, Spain
| | - C Navarro-Soriano
- Pneumology Department, Hospital Universitario i Politécnico la Fe, Valencia, Spain
| | - A Muriel
- Biostatistic Unit, Hospital Ramón y Cajal. IRYCIS, CIBERESP, Nursery Department and Physiotherapy, Alcalá University, Madrid, Spain
| | - D Gozal
- Department of Child Health, University of Missouri, Columbia, MO, USA
| |
Collapse
|